Latest research on Daptomycin

Daptomycin is a lipopeptide antibiotic that kills susceptible gram positive bacteria by disrupting their membrane potential. It is a naturally-occurring compound found in the soil bacterium Streptomyces roseosporus. Antibiotics are used in the treatment of infections caused by bacteria. They work by killing bacteria or preventing their growth. Daptomycin will not work for colds, flu, or other virus infections. It was approved in September 2003 for the treatment of complicated skin and soft tissue infections. It has a safety profile similar to other agents commonly administered to treat gram-positive infections.

Daptomycin indications

No adverse effect related to Daptomycin, such as myositis, rhabdomyolysis, peripheral neuropathy, derangement of liver function or eosinophilic pneumonia was observed in our study. [source, 2016]
We attributed the results to the readiness of Daptomycin release from the PMMA bone cement and its excellent bactericidal effect against methicillin-resistant strains. [source, 2016]
In another study, severe side effects (one case of acute renal failure due to massive rhabdomyolysis, one of eosinophilic pneumonia and 2 cases of asymptomatic transient CPK level elevation) were also reported with Daptomycin at a dose of 6.6 mg/kg/day for an average of 44.9 days in the treatment of PJI [13]. [source, 2016]
No patient experienced any severe adverse effects related to Daptomycin. [source, 2016]
This could reduce the confounding effect if systemic Daptomycin were used. [source, 2016]
Due to adverse effects and treatment failures, Q/D should be considered as an alternative option for VRE infections after the use of Linezolid or Daptomycin. [source, 2015]
Risk factors, including HA-MRSA, MRSA with Vancomycin MIC ≥ 1.5 mg/L, teicoplanin MIC ≥ 1.5 mg/L, and Daptomycin MIC ≥ 0.38 mg/L, were associated with each other and the combined effect is a higher risk of mortality in the bacteremic patients. [source, 2015]
In summary, MIC of Vancomycin, teicoplanin and Daptomycin must be checked in 2 days for choosing an effective initial antibiotic therapy for patients with MRSA bacteremia. [source, 2015]
A microbiological method has been properly developed and validated and shown to be effective for determining the potency of Daptomycin in the pharmaceutical dosage form of lyophilized powder for injectable solution, since it was linear, precise, accurate, robust and selective. [source, 2015]
Nevertheless, the most promising formulations for the Antibacterial effect assessment would be those with higher DL (ie, mg of antibiotic/mg of microparticles), which in this case are the microparticles loaded with 30% Daptomycin or Vancomycin. [source, 2015]